Stock Price Forecast

Sept. 8, 2023


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Surface Oncology Inc chart...

About the Company

surface oncology was created to advance next‐generation approaches to cancer immunotherapy based on proprietary insights about novel immunotherapy targets and emerging areas of cancer immuno‐biology. the company’s scientific founders and sab are comprised of world‐leading immunologists and cancer researchers, including co‐chairs sasha rudensky (memorial sloan kettering) and arlene sharpe (harvard/dfci). they are joined on the sab by christopher hunter and john wherry (university of pennsylvania), carla rothlin (yale university), elliott sigal, and john stagg (university of montreal). surface oncology recently completed a $35 million series a financing round with a-list backers. atlas venture, which seeded the company in 2014, led the round, joined by new enterprise associates, fidelity biosciences, lilly ($lly) ventures, amgen ($amgn) ventures, novartis ($nvs) institute for biomedical research, and elliott sigal, the former head of r&d at bristol-myers. for more information, visit ww

$-3M

Total Revenue

90

Employees

$65M

Market Capitalization

-0.67

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $SURF News

The Resilience of Monoclonal Antibodies and their Makers

3d ago, source: The Scientist

The road to developing monoclonal antibodies for effectively targeting cancer was paved with tenacity, passion, and strokes ...

Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update

5d ago, source:

Net revenue of $91.5 million in the fourth quarter and $257.2 million in FY 2023 – – UDENYCA® net sales of $36.2 million in the fourth quarter ...

ALX Oncology Holdings Inc (ALXO) Reports Growth Amidst Increased R&D Spending

11d ago, source: Yahoo Finance

On March 7, 2024, ALX Oncology Holdings Inc (NASDAQ:ALXO) released its 8-K filing ... a CD47 blocker in phase 1 and 2 clinical trials. CD47 is a cell surface protein that cancer cells exploit to evade ...

Key Health Care Issues to Track in 2024 in Alabama

13d ago, source: JD Supra

[i] In North Alabama, Huntsville Emergency Medical Services Inc. (HEMSI) merged with the Huntsville Hospital Health System as of January 2024. [ii] 3. Expansion of Healthcare Providers. In an effort ...

Studying use of patients’ own reprogrammed cells to attack cancer as alternative to more chemo

on MSN ago, source:

A process of taking patients’ own cells and reprogramming them to fight cancer has been a last-ditch option for blood cancer ...

Living drugs that reprogram patients’ immune cells show early promise against hard-to-treat brain tumors

6d ago, source: WRAL

“That was shocking to me,” said Dr. Otis Brawley, a professor of oncology at Johns Hopkins University and ... in a lab so they’d recognize and bind to specific proteins on the surface of the brain ...

Merck & Co., Inc.: Merck Looks Well Positioned With Keytruda, Gardasil, and a Strengthening Pipeline

1mon ago, source:

Find the latest Merck & Company, Inc. (MRK) stock forecast based on top analyst's estimates, plus more investing and trading data from Yahoo Finance ...

Provectus Biopharmaceuticals Announces Acceptance of Cancer Immunotherapy PV-10 Abstract for HNSCC at AACR 2024 Annual Meeting

11d ago, source:

Moffitt’s preclinical findings strongly suggest PV-10 induces immunogenic cell death-associated immunogenicity in HPV-positive and HPV-negative ...

1 (Bad) Reason to Sell Moderna Stock Right Now, and 2 Good Reasons to Buy It

on MSN ago, source:

It's always possible to come up with a justification for why someone should sell their shares of a stock, but that doesn't make every justification correct. For a company like Moderna (NASDAQ: MRNA) ...

Kyverna Therapeutics and Stanford University Agree to Evaluate KYV-101 in Patients with Non-Relapsing and Progressive Forms of Multiple Sclerosis

12d ago, source:

NDAQ:KYTX) Kyverna Therapeutics and Stanford University Agree to Evaluate KYV-101 in Patients with Non-Relapsing and Progressive Forms of Multiple Sclerosis ...

FDA Clears Clinical Study of Vaccine Therapy for Ovarian Cancer

13d ago, source: Targeted Oncology

The first-in-human study that has received FDA clearance will investigate the novel autologous Innocell vaccine in stage ...

Q4 2023 Heron Therapeutics Inc Earnings Call

5d ago, source:

Kevin Warner; SVP of Medical Affairs strategy engagements; Heron Therapeutics Inc William Forbes; EVP, Chief Development Officer; Heron Therapeutics Inc Ira Duarte; Chief Financial Officer; Heron ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...